Approximately 96 COVID-19 vaccines are at various stages of clinical development.1 At present, we have the interim results of four studies published in scientific journals (on the Pfizer–BioNTech BNT162b2 mRNA vaccine,2 the Moderna–US National Institutes of Health [NIH] mRNA-1273 vaccine,3 the AstraZeneca–Oxford ChAdOx1 nCov-19 vaccine,4 and the Gamaleya GamCovidVac [Sputnik V] vaccine)5 and three studies … Continue reading #COVID-19 #vaccine efficacy and effectiveness—the elephant (not) in the room
Tag: Vaccines
Unprecedented loss of life due to the COVID pandemic has necessitated the development of several vaccines in record time. Most of these vaccines have received approval without being extensively whetted for their adverse effect and efficacy profiles. Most adverse effects have been mild, nonetheless, more serious thromboembolic events have also been reported. Autoimmune hepatitis (AIH) … Continue reading Auto-immune #hepatitis following #COVID vaccination
Influenza viruses grown in eggs for the purposes of vaccine generation often acquire mutations during egg adaptation or possess different glycosylation patterns than viruses circulating among humans. Here, we report that seasonal influenza virus vaccines possess an egg-derived glycan that is an antigenic decoy, with egg-binding MAbs reacting with a sulfated N-acetyllactosamine (LacNAc). Half of … Continue reading An #Egg-Derived Sulfated N-Acetyllactosamine Glycan Is an Antigenic Decoy of Influenza Virus #Vaccines
..Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary … Continue reading Tolerability and Immunogenicity After a Late Second #Dose or a Third Dose of ChAdOx1 #nCoV-19 (AZD1222)
